The invention features methods compositions and infusion pumps for infusing levodopa prodrugs (e.g. levodopa esters levodopa amides levodopa carboxamides and levodopa sulfonamides) for the treatment of Parkinson's disease.

The present invention relates to extended-release pharmaceutical dosage forms of carbidopa and levodopa comprising: a first component comprising a first portion of carbidopa and levodopa; a second component comprising a second portion of carbidopa and levodopa; and a third component comprising a third portion of carbidopa levodopa and carboxylic acid. The present invention also relates to processes for the preparation of said extended-release pharmaceutical dosage forms. The present invention fu...

FIELD: medicine pharmaceutics.SUBSTANCE: present invention refers to chemical-pharmaceutical industry and presents using (-)-(3aR4S7aR)-4-hydroxy-4-m-tolylethinyloctahydroindole-1-carboxylic acid methyl ester for treating preventing or arresting the development of dyskinesia caused by levodopa (L-dopa) in treating Parkinson's disease.EFFECT: invention refers to a pharmaceutical composition a kit and a foodstuff containing (-)-(3aR4S7aR)-4-hydroxy-4-m-tolylethinyloctahydroindole-1-carboxylic acid...

Provided herein in part is a method of treating a neurological or movement disorder in a patient in need thereof comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone or pharmaceutically acceptable salts thereof wherein said composition is administered substantially continuously and compositions that can be used in the disclosed methods.

The present invention provides compounds of Formula (I) that are GPR6 modulators and are therefore useful for the treatment of diseases treatable by modulation of GPR6, in particular treating Parkinson disease, levodopa induced dyskinesias, Huntington's disease, other dyskinesias, akinesias, and motor disorders involving dysfunction of the striatum, schizophrenia and drug addiction. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds...

The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa a decarboxylase inhibitor and a carboxylic acid. Also provided by this invention is multiparticulate controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of l...